NCT03450902

Brief Summary

The purpose of this study is to determine whether combination therapy with Chinese herbal formula, Yiqi Suoquan granule, and acupuncture is effective in the treatment of female mixed urinary incontinence.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
136

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Mar 2018

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 23, 2018

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 1, 2018

Completed
13 days until next milestone

Study Start

First participant enrolled

March 14, 2018

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 18, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 18, 2021

Completed
Last Updated

June 1, 2021

Status Verified

May 1, 2021

Enrollment Period

3.1 years

First QC Date

February 23, 2018

Last Update Submit

May 28, 2021

Conditions

Keywords

Urinary incontinence, Chinese herb, Acupuncture

Outcome Measures

Primary Outcomes (1)

  • Change in incontinence episode per 24 h

    assessed by 72 h bladder diary

    8 week (post-treatment) and 12 week (follow-up)

Secondary Outcomes (3)

  • Change in ICIQ-SF questionnaire

    8 week (post-treatment) and 12 week (follow-up)

  • Change in I-QOL questionnaire

    8 week (post-treatment) and 12 week (follow-up)

  • proportion of participants with more than 50% improvement in incontinence episodes per 24h

    8 week (post-treatment)

Study Arms (4)

Chinese herb & acupuncture

EXPERIMENTAL

Participants will take Yiqi Suoquan granule and receive acupuncture.

Combination Product: Chinese herb & sham acupunctureCombination Product: Placebo & acupunctureOther: Placebo & sham acupuncture

Chinese herb & sham acupuncture

ACTIVE COMPARATOR

Participants will take Yiqi Suoquan granule and receive sham acupuncture.

Combination Product: Chinese herb & acupunctureCombination Product: Placebo & acupunctureOther: Placebo & sham acupuncture

Placebo & acupuncture

ACTIVE COMPARATOR

Participants will take placebo granule and receive acupuncture.

Combination Product: Chinese herb & acupunctureCombination Product: Chinese herb & sham acupunctureOther: Placebo & sham acupuncture

Placebo & sham acupuncture

PLACEBO COMPARATOR

Participants will take placebo granule and receive sham acupuncture.

Combination Product: Chinese herb & acupunctureCombination Product: Chinese herb & sham acupunctureCombination Product: Placebo & acupuncture

Interventions

Chinese herb & acupunctureCOMBINATION_PRODUCT

Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.

Also known as: Yiqi Suoquan granule & acupuncture
Chinese herb & sham acupuncturePlacebo & acupuncturePlacebo & sham acupuncture

Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.

Also known as: Yiqi Suoquan granule & sham acupuncture
Chinese herb & acupuncturePlacebo & acupuncturePlacebo & sham acupuncture
Placebo & acupunctureCOMBINATION_PRODUCT

Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.

Also known as: placebo granule & acupuncture
Chinese herb & acupunctureChinese herb & sham acupuncturePlacebo & sham acupuncture

Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.

Also known as: placebo granule & sham acupuncture
Chinese herb & acupunctureChinese herb & sham acupuncturePlacebo & acupuncture

Eligibility Criteria

Age18 Years - 65 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • (1) female, leaking with urgency and with physical activity, coughing or sneezing (MUI) for more than 1 year; (2) recorded more than 1 incontinent episode per 24 hours in their bladder diary

You may not qualify if:

  • (1) with acute urinary tract infection; (2) with bladder outlet obstruction, (3) with neurogenic bladder (4) with interstitial cystitis, (5) with pelvic organ prolapse more than stage 2 (6) previous anti-incontinence surgery or a post-void residual urine volume more than 100 mL.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Beijing, Beijing Municipality, 100053, China

Location

MeSH Terms

Conditions

Urinary Incontinence

Interventions

Acupuncture Therapy

Condition Hierarchy (Ancestors)

Urination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesLower Urinary Tract SymptomsUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Complementary TherapiesTherapeutics

Study Officials

  • Ran Pang, MD

    Guang'anmen hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

February 23, 2018

First Posted

March 1, 2018

Study Start

March 14, 2018

Primary Completion

April 18, 2021

Study Completion

April 18, 2021

Last Updated

June 1, 2021

Record last verified: 2021-05

Data Sharing

IPD Sharing
Will not share

The agreement for sharing IPD is not designed to be signed in informed consent form.

Locations